The company expects its total 2020 revenue to be between $8.4 billion and $8.8 billion, up from its previous outlook of $8 billion to $8.6 billion.
Cash provided by operations for the full year is now expected to be at least $1.45 billion, compared to the previous outlook of at least $1.25 billion.
Quest said since reporting its second quarter results July 23, its organic testing volumes have recovered faster than anticipated. Its COVID-19 molecular and antibody testing volumes have remained consistent with the previous outlook.
The company said the pandemic’s impact on its future operating results will be primarily driven by factors beyond the company’s knowledge and control, including how long the pandemic lasts, how severe it is in the future, the economic effects and the scope of federal, state and local governmental responses.
Read the full news release here.
More articles on supply chain:
Boston lab halts COVID-19 testing after nearly 400 false positives
Faster COVID-19 test results trump more precise tests, public health experts say
Roche gets emergency approval for combination flu, COVID-19 test
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
